Genmab Past Earnings Performance
Past criteria checks 4/6
Genmab has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 23.8% per year. Genmab's return on equity is 14.7%, and it has net margins of 23.7%.
Key information
10.2%
Earnings growth rate
10.0%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 23.8% |
| Return on equity | 14.7% |
| Net Margin | 23.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genmab makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 19,844 | 4,702 | 3,475 | 9,032 |
| 30 Jun 24 | 19,016 | 5,540 | 3,470 | 8,773 |
| 31 Mar 24 | 17,783 | 5,467 | 3,478 | 8,189 |
| 31 Dec 23 | 16,474 | 4,352 | 3,297 | 7,630 |
| 30 Sep 23 | 16,852 | 4,163 | 3,284 | 7,285 |
| 30 Jun 23 | 16,227 | 4,641 | 3,094 | 6,683 |
| 31 Mar 23 | 15,220 | 5,197 | 2,900 | 6,112 |
| 31 Dec 22 | 14,505 | 5,452 | 2,676 | 5,524 |
| 30 Sep 22 | 11,987 | 5,654 | 2,267 | 5,219 |
| 30 Jun 22 | 10,210 | 3,962 | 1,903 | 4,847 |
| 31 Mar 22 | 9,020 | 2,377 | 1,534 | 4,486 |
| 31 Dec 21 | 8,417 | 2,957 | 1,283 | 4,181 |
| 30 Sep 21 | 7,907 | 2,873 | 1,002 | 3,787 |
| 30 Jun 21 | 7,321 | 2,513 | 841 | 3,394 |
| 31 Mar 21 | 10,800 | 5,585 | 756 | 3,248 |
| 31 Dec 20 | 10,111 | 4,758 | 661 | 3,137 |
| 30 Sep 20 | 11,028 | 5,649 | 546 | 2,880 |
| 30 Jun 20 | 10,344 | 5,656 | 483 | 2,766 |
| 31 Mar 20 | 5,667 | 2,363 | 377 | 2,555 |
| 31 Dec 19 | 5,366 | 2,166 | 342 | 2,386 |
| 30 Sep 19 | 3,641 | 1,528 | 285 | 2,173 |
| 30 Jun 19 | 3,199 | 1,170 | 258 | 1,910 |
| 31 Mar 19 | 2,935 | 1,345 | 241 | 1,664 |
| 31 Dec 18 | 3,025 | 1,472 | 214 | 1,431 |
| 30 Sep 18 | 2,807 | 1,424 | 195 | 1,227 |
| 30 Jun 18 | 2,532 | 1,239 | 177 | 1,112 |
| 31 Mar 18 | 2,796 | 1,286 | 157 | 995 |
| 31 Dec 17 | 2,365 | 1,104 | 147 | 852 |
| 30 Sep 17 | 2,275 | 1,159 | 131 | 795 |
| 30 Jun 17 | 2,316 | 1,354 | 121 | 718 |
| 31 Mar 17 | 1,897 | 1,215 | 110 | 704 |
| 31 Dec 16 | 1,816 | 1,187 | 102 | 661 |
| 30 Sep 16 | 1,463 | 735 | 101 | 642 |
| 30 Jun 16 | 1,376 | 686 | 94 | 606 |
| 31 Mar 16 | 1,196 | 535 | 93 | 529 |
| 31 Dec 15 | 1,133 | 764 | 91 | 488 |
| 30 Sep 15 | 774 | 443 | 92 | 443 |
| 30 Jun 15 | 768 | 463 | 90 | 441 |
| 31 Mar 15 | 710 | 420 | 86 | 459 |
| 31 Dec 14 | 850 | 301 | 80 | 506 |
| 30 Sep 14 | 851 | 292 | 77 | 517 |
| 30 Jun 14 | 729 | 138 | 72 | 534 |
| 31 Mar 14 | 751 | 138 | 69 | 545 |
| 31 Dec 13 | 664 | 70 | 67 | 528 |
Quality Earnings: 0MGB has high quality earnings.
Growing Profit Margin: 0MGB's current net profit margins (23.7%) are lower than last year (24.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0MGB's earnings have grown by 10.2% per year over the past 5 years.
Accelerating Growth: 0MGB's earnings growth over the past year (12.9%) exceeds its 5-year average (10.2% per year).
Earnings vs Industry: 0MGB earnings growth over the past year (12.9%) exceeded the Biotechs industry -20.8%.
Return on Equity
High ROE: 0MGB's Return on Equity (14.7%) is considered low.